KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest & Investment Income (2023 - 2025)

Nektar Therapeutics (NKTR) has 8 years of Interest & Investment Income data on record, last reported at $2.8 million in Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 17.98% year-over-year to $2.8 million; the TTM value through Sep 2025 reached $10.6 million, down 34.44%, while the annual FY2024 figure was $14.5 million, 23.72% down from the prior year.
  • Interest & Investment Income reached $2.8 million in Q3 2025 per NKTR's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.2 million in Q3 2023 and bottomed at $2.0 million in Q2 2025.
  • Average Interest & Investment Income over 3 years is $3.7 million, with a median of $3.9 million recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: fell 2.65% in 2024, then plummeted 49.53% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at $4.6 million in 2023, then plummeted by 36.28% to $2.9 million in 2024, then fell by 4.18% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $2.8 million in Q3 2025, $2.0 million in Q2 2025, and $2.9 million in Q1 2025.